Dianthus Therapeutics to Participate in Two Investor Conferences

Dianthus Therapeutics (Nasdaq: DNTH) will participate in two investor conferences in June 2026.

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) will participate in two investor conferences in June 2026. Executives will join fireside chats and host one-on-one investor meetings at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.

Live webcasts will be available via the company’s investor relations website under “News and Events”.

Argus May 27 session

-0.17% close to close Open Argus

Details

News Market Reaction – DNTH

In the May 27 session, DNTH declined 0.17%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines Dianthus’s participation in two major healthcare investor conferences in ...

Analysis

This announcement outlines Dianthus’s participation in two major healthcare investor conferences in June 2026, providing additional visibility following recent earnings, trial progress, and sizeable financings. The company has an effective shelf for up to $600M of securities and has recently completed upsized offerings, so investors may watch how management discusses capital allocation, clinical timelines, and strategic priorities during these fireside chats and one-on-one meetings.

Key Figures

Number of conferences: 2 conferences Jefferies chat time: 12:45 p.m. ET Goldman Sachs chat time: 2:40 p.m. ET +2 more

Number of conferences

2 conferences

Investor events scheduled for June 2026

Jefferies chat time

12:45 p.m. ET

June 3, 2026 Jefferies Global Healthcare Conference fireside chat

Goldman Sachs chat time

2:40 p.m. ET

June 9, 2026 Goldman Sachs Global Healthcare Conference fireside chat

Conference month/year

June 2026

Timing of the two scheduled investor conferences

Goldman Sachs conference edition

47th Annual

Goldman Sachs 47th Annual Global Healthcare Conference

Historical Context

5 past events · Latest: May 05

5 events

1. May 05

   Earnings and pipeline

   24h Move

   +0.2%

   Q1 2026 results, trial progress, Orphan Drug Designation, and strong cash runway.

2. May 01

   Inducement grants

   24h Move

   +2.2%

   Stock option inducement awards to new employees under Nasdaq Rule 5635(c)(4).

3. Apr 06

   Inducement grants

   24h Move

   +0.8%

   Additional non-qualified stock option grants to new non-executive employees.

4. Mar 12

   Offering closing

   24h Move

   -3.1%

   Closing of upsized public offering raising about $719M in gross proceeds.

5. Mar 10

   Offering pricing

   24h Move

   -1.2%

   Pricing of upsized $625M underwritten public offering with common shares and warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in two investor conferences in June 2026.

Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, will participate in a fireside chat on Wednesday, June 3, 2026, at 12:45 p.m. ET and will host one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference.

Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET and will host one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference.

Webcasts of these presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Dianthus Therapeutics (DNTH) present at the Jefferies Global Healthcare Conference 2026?

Dianthus Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 12:45 p.m. ET. EVP, CFO and CBO Ryan Savitz will participate in a fireside chat and investor meetings.

Who will represent Dianthus Therapeutics (DNTH) at the Goldman Sachs 47th Annual Global Healthcare Conference 2026?

Marino Garcia, CEO of Dianthus Therapeutics, will represent the company at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 2:40 p.m. ET, including a fireside chat and one-on-one investor meetings.

How can investors access the June 2026 Dianthus Therapeutics (DNTH) conference webcasts?

Investors can access the June 2026 conference webcasts under “News and Events” in the Investors section of the Dianthus Therapeutics website. The company plans to stream both fireside chats online for remote participants.

What is the purpose of Dianthus Therapeutics (DNTH) participating in June 2026 investor conferences?

Participation allows Dianthus Therapeutics to engage with investors through fireside chats and one-on-one meetings. According to the company, these June 2026 events provide a platform to discuss its clinical-stage pipeline and strategy with the healthcare investment community.

Which executives from Dianthus Therapeutics (DNTH) are speaking at June 2026 investor events?

Dianthus Therapeutics executives Ryan Savitz (EVP, CFO and CBO) and Marino Garcia (CEO) are scheduled speakers. They will each join a fireside chat and host one-on-one investor meetings at separate June 2026 healthcare conferences.

Where can shareholders find details on Dianthus Therapeutics (DNTH) June 2026 conference schedule?

Shareholders can find details on the company’s June 2026 conference schedule in the Investors section of the Dianthus Therapeutics website. According to the company, information is listed under the “News and Events” area with webcast links.